Supraventricular Tachycardia (SVT)
Conditions
Keywords
diltiazem, adenosine, emergency medicine, supraventricular tachycardia
Brief summary
Supraventricular tachycardia (SVT) is a dysrhythmia characterized rapid heart rate, typically with rapid onset. SVT accounts for over 50,000 emergency department visits per year. Of patients with regular, narrow-complex SVT, the mainstay of therapy includes adenosine and diltiazem. Adenosine is recommend by American and European guidelines as first-line therapy, however adenosine carries unique side effects that are potentially distressing to patients, including: "feeling of impending death or doom", flushing, anxiety, shortness of breath, and chest discomfort. Diltiazem does not carry this side effect profile, but has typically been reserved as second-line treatment due to side effects of low blood pressure associated with this class of medications. Diltiazem and adenosine have not been well studied head-to-head to compare safety and efficacy of their treatment for SVT. The purpose of this study is to evaluate safety and efficacy of adenosine and diltiazem for SVT in the ED (as completed through chart review of specific patient-level outcomes) and capture patient and clinician perspectives of medication satisfaction (through administration of questionnaires).
Interventions
DRUGIV adenosine
Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment
DRUGIV diltiazem
Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment
Sponsors
University of Iowa
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. ED encounter for acute SVT 2. Age \>/= 18 years 3. Receipt of IV adenosine and/or IV diltiazem for SVT in the ED or prehospital setting
Exclusion criteria
1. Neurologic status precluding survey participation due to medical instability 2. Pregnant 3. Incarcerated 4. Non-English speaking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient satisfaction with SVT treatment | Primary outcome will be assessed during ED visit | Patient satisfaction with treatment will be assessed using a Likert scale questionnaire of 1-5. Participants will indicate their satisfaction with treatment by indicating a score of 1-5, 1 being "not at all satisfied" and 5 being "extremely satisfied". |
Countries
United States
Contacts
CONTACTAnne Zepeski, PharmD
Outcome results
None listed